Tuberculosis (TB) and non-tuberculous mycobacterial pulmonary disease (NTM-PD) are complex immuno-pathological diseases that are extremely difficult to treat. Standard drug regimens are usually composed of 3 to 4 antibiotics that are administered daily during several months. These heavy and long antibiotic treatments are frequently responsible for serious adverse effects which impact the observance of many patients, leading to treatment failures, relapses or the emergence of multi-drug resistant strains.

In the lab, our research aims at understanding the molecular and cellular bases involved in mycobacterial adaptation and pathogenesis within the host, but also identify molecular mechanisms underlying antibiotic mode(s) of action, efficacy and drug resistance within in vitro and in cellulo biological systems.

We combine bioinformatic and biochemical studies with innovative mycobacterial genetics, host-pathogen interactions and quantitative imaging approaches to uncover new adaptation strategies, antibiotic mode(s) of action and resistance mechanisms at multiple-scale. 

With this toolkit we explore new biological concepts regarding antibiotic efficacy and chemotherapy of mycobacterial infections. Our main goal being to provide ground-breaking answers to key fundamental questions, which might benefit basic researchers, clinicians and ultimately patients by informing new strategies to improve antibiotic therapy for pulmonary disease.

Our lab is always looking for strong and excellent prospective Master/PhD/PostDoc candidates, so feel free to contact us if you are interested in joining the lab!